Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis - Summary - MDSpire

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • By

  • Onur Baş

  • Bediz Kurt İnci

  • İmdat Eroğlu

  • Safa Can Efil

  • Seher Kaya

  • Pınar Kubilay Tolunay

  • Taha Koray Şahin

  • Cengiz Karaçin

  • Ozan Yazıcı

  • Mehmet Ali Nahit Şendur

  • Berna Ömür Çakmak Öksüzoğlu

  • Sercan Aksoy

  • November 28, 2025

  • 0 min

Share

Objective:

To investigate ribociclib-induced hepatotoxicity and compare survival rates between patients with different grades of hepatotoxicity, specifically focusing on grade 1–2 versus grade 3–4.

Key Findings:
  • 9.2% of patients developed hepatotoxicity, with 6.4% having grade 4, 24.4% grade 3, and 69.2% grade 1 toxicity.
  • Patients with grade 3–4 hepatotoxicity had decreased overall survival (OS) compared to those with grade 1–2 (90% vs 76% at one year).
  • The median time to onset of hepatotoxicity was 13 weeks after ribociclib initiation.
Interpretation:

Ribociclib-induced hepatotoxicity is a significant concern, with higher grades of toxicity associated with poorer survival outcomes.

Limitations:
  • The study is retrospective and may have biases related to data collection, including selection bias and reporting bias.
  • The sample size of patients with hepatotoxicity is relatively small, which may limit the generalizability of the findings.
Conclusion:

Ribociclib-induced hepatotoxicity is clinically relevant, and its management is crucial for improving patient outcomes.

Original Source(s)

Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis

  • by Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy

  • November 28, 2025

Related Content

A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications